A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer

This study is a multicenter, single-arm, prospective, open clinical study to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, albumin paclitaxel, and carboplatin in neoadjuvant therapy for ER+/HER2+ early or locally advanced breast cancer.

Trial Details

NCT ID

NCT06000917

Phase

PHASE2

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel

Locations (sample)

Wuhan, Hubei, China|30.58333,114.26667
Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

Newly treated female patients aged ≥18 years and ≤75 years;
ECOG score 0\~1;
Pathologically diagnosed as HER2-positive breast cancer patients with early or locally advanced tumor stage, primary tumor diameter T≥2cm or lymph …
Hormone receptor status (ER and PgR) is known, where ER≥10%

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →